Welcome to ZIKAVAX, a collaborative project funded under the European Union’s Horizon 2020 Research and Innovation Programme (H2020) and coordinated by the European Vaccine Initiative (EVI). The four-year project was initiated in October 2016 and has an overall budget of approximately € 5 million. The project is the joint effort of leading European experts from academia and industry with unique and specific technological expertise in viral vectors and vaccine development.
The ZIKAVAX project aims at developing a safe, effective, and affordable preventive vaccine against Zika virus infection. To achieve this goal, ZIKAVAX will use a delivery platform technology based on a measles vector (MV) with demonstrated proof of principle in humans and a preclinical track record of rapid adaptability and effectiveness for a variety of pathogens. In ZIKAVAX, following antigen selection and expression, immunisation studies will be conducted with the Zika vaccine candidate in mice and in a non-human primates challenge model that will be developed by the consortium. The ultimate goal of ZIKAVAX is the demonstration of safety and immunogenicity of a recombinant measles-Zika vaccine candidate (MV-ZIKA) in adult volunteers in a phase Ia clinical trial.
ZIKAVAX partners at the first annual meeting 7 December 2017 at CEA, Fontenay-aux-Roses, France.